Clinical Trial Update: Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy and safety of tildrakizumab in adults with moderate-to-severe chronic plaque psoriasis who did not respond to dimet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: Almirall, S.A. | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED